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Abstract. We are being confronted with the most consequen-
tial pandemic since the Spanish flu of 1918‑1920 to the extent 
that never before have 4 billion people quarantined simultane-
ously; to address this global challenge we bring to the forefront 
the options for medical treatment and summarize SARS-coV2 
structure and functions, immune responses and known treat-
ments. Based on literature and our own experience we propose 
new interventions, including the use of amiodarone, simv-
astatin, pioglitazone and curcumin. In mild infections (sore 
throat, cough) we advocate prompt local treatment for the 
naso‑pharynx (inhalations; aerosols; nebulizers); for moderate 
to severe infections we propose a tried-and-true treatment: the 
combination of arginine and ascorbate, administered orally 
or intravenously. The material is organized in three sections: 
i) Clinical aspects of COVID‑19; acute respiratory distress 
syndrome (ARdS); known treatments; ii) Structure and func-
tions of SARS-coV2 and proposed antiviral drugs; iii) The 
combination of arginine-ascorbate.
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In China, the first comprehensive analysis published on the 
COVID‑19 (1) included 44,672 cases and 1,023 deaths, with an 
overall case-fatality rate (cFR) of 2.3%. There were 0 deaths 
in patients 9 years old or younger, and the cFR increased with 
advancing age (70‑79 years: 8.0%, 80 years and older: 14.8%) 
and also with comorbid conditions: 5.6% for cancer, 6.0% for 
hypertension, 7.3% for diabetes, 10.5% for cardiovascular 
disease; for intensive care patients cFR was 49.0%. Similar data 
were published by other authors on the china epidemic (2,3); 
another analysis (4) identified 3 biological markers associated 
with the severity of the infection and progression to ARdS 
and death: i) neutrophilia; ii) increased lactate dehydrogenase 
LdH and iii)  coagulation dysfunction (d-dimer). There were 
2 unexpected findings: i) patients with fever ≥39˚C were 
more likely to develop ARdS but also less likely to die; and 
ii) administering methylprednisolone to patients with ARdS 
was associated with lower risk of death.
In Europe there was a higher rate of severe cases in 
Italy (5,6) where 12% of positive patients were admitted 
to IcU vs. 5% in china; this difference was attributed to a 
higher proportion of elderly and increased social contact (7,8). 
Data from Germany (9) showed that ~1/3 of admitted patients 
had leucopenia and most of these (80%) had lymphopenia; 
c-reactive protein (cRP) was often increased and very high 
cRPs were associated with a less favorable outcome for 
the patient. Approximately 40% of admitted patients had 
increased LDH, D‑dimer and/or thrombocytopenia, and an 
LDH value of >400 IU/ml was associated with more severe 
disease. Troponin was increased in a small number of patients, 
with unclear significance.
In the USA, a recent publication showed that a majority (71%) 
of COVID‑19 patients with ARDS and in intensive care, also 
had hypotension (10,11). There is already an extensive clinical 
experience with ARDS in the USA, where >180,000 patients 
annually are admitted with this pathology and ARdS mortality 
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has improved from 40 to 50% 10 years ago to 20‑25% in recent 
clinical trials. A group of USA intensive care specialists led by 
dr calfee has analyzed >30 biomarkers and clinical variables 
from two large clinical trials on ARDS (12); subsequently an 
ARdS patient population was identified which comprised 
~30% of total ARdS cases, had higher levels of IL-6 and IL-8, 
more patients with sepsis and in need for vasopressor treat-
ment, with higher mortality but also responding better to high 
positive expiratory‑end pressure (PEEP) therapy. With data 
from more clinical trials (13), two ARDS populations were 
identified, the hypoinflammatory and hyperinflammatory 
subphenotypes, with distinctive and opposite characteristics. 
The former has low levels of IL-6, IL-8, tumor necrosis factor 
receptor 1 (TNFr1), lower mortality as well as higher number 
of ventilator-free days, high bicarbonate and protein c; the 
latter has high levels of IL‑6, IL‑8, TNFr1, low levels of bicar-
bonate and protein c, low number of ventilator-free days and 
higher mortality.
Treatment-wise, the same group showed that in the ARdS 
hyperinflammatory subphenotype better outcomes were 
obtained with administration of high PEEP, liberal fluid 
strategy (vs. conservative fluid administration) and simvastatin, 
while rosuvastatin administration was of no benefit (12,14‑16); 
Table I summarizes the data from different clinical trials on 
ARdS subphenotypes. The observed difference between 
statins in ARDS may be explained by their solubility: while 
simvastatin is lipid-soluble, rosuvastatin is water-soluble, with 
important consequences on cell membrane interaction.
It is safe to say that COVID‑19 patients who develop ARDS 
(with high levels of interleukins, low blood pressure) belong 
to the hyperinflammatory subphenotype and may benefit 
from the therapeutic insight associated with this group of 
patients (higher PEEP, liberal fluid strategy, and simvastatin). 
In critically‑ill COVID‑19 patients, increased LDH levels 
are likely associated with acidosis and if low blood pressure 
is also present, before vasopressors they are likely to benefit 
from administration of sodium bicarbonate (increments of 
100 ml of 8.4% solution).
Treatment-wise, after the SARS and MERS epidemics a 
few antivirals were proposed and tested and among these are 
mycophenolic acid, cyclosporine at low concentrations, chlo-
roquine; chlorpromazine, loperamide, and lopinavir, found 
to be broad‑spectrum coronavirus inhibitors (17). Recently 
FDA has approved remdesivir (GS5734 ‑ an RNA polymerase 
inhibitor) as specific treatment for COVID‑19; different proto-
cols use chloroquine (500 mg q 12 h); hydroxychloroquine 
(200 mg q 12 h); lopinavir/ritonavir (400/100 mg every 12 h), 
α-interferon (aerosol inhalation 5 million IUbid), and there are 
>50 treatments tested in clinical trials (18).
For ARDS, as the most severe form of COVID‑19 infection, 
there is ample data from proteomics showing highly activated 
pathways of inflammation, increased levels of eosinophil‑ and 
neutrophil-derived proteins, epithelial and endothelial injury, 
matrix metalloproteinase 7 (MMP7), α- and β-hemoglobin, 
apolipoprotein A1, osteopontin and chemokines (19,20). The 
context of increased inflammation in ARDS justifies the use 
of biological agents, antagonists of the IL-6 receptor (IL-6R), 
and TNF-α, such as infliximab, rituximab, ustekinumab, 
etanercept, adalimumab and tocilizumab (18). However, 
the complexity of living biological systems with redundant 
pathways and dual-role modulators means that they do not 
always conform to mechanistic determinism, and this is espe-
cially true in patients with chronic diseases or co-morbid 
conditions, where modifications of physiological pathways 
translate into unknown but important factors with unexpected 
consequences. One such example is a clinical trial for sepsis 
which tested a recombinant IL‑1 receptor antagonist (IL‑1Ra) 
with negative results, but at the same time benefited patients 
with higher baseline levels of IL‑1Ra (21).
Another important aspect is that multiple cellular pathways 
besides inflammation are simultaneously affected in ARDS, 
including coagulation, endothelial and epithelial injury path-
ways (apoptosis) and healing (fibrosis) in lungs. A unique 
molecular signature of lethal infection with another respira-
tory virus (PR8, an influenza virus) showed over‑activation of 
pro‑inflammatory pathways, NF‑κB, IL-6, TNF and neutro-
phil chemotaxis (22), associated decreased activation of genes 
involved in lung homeostasis and repair. Neutrophils with high 
pro‑inflammatory activity were numerous in lung infiltrates, 
their own chemokines further promoted neutrophil influx in 
a positive feedback loop; a dose-dependent survival was seen 
with partial neutrophil depletion in this type of lethal infection. 
comparing viral replication in non-lethal vs. lethal infection 
they had similar viral replication rates, but the lethal infection 
had increased viral titers in the lungs, and also increased early 
pro‑inflammatory neutrophil activation, resulting in pathologic 
neutrophil infiltration and fatal lung damage (23). Similar 
observations increased neutrophil- and neutrophil-attracting 
chemokines, delay in induction of IFN in airway epitlelial cells 
resulting in vascular leakage and lung damage were made in 
SARS and MERS suggesting a common pathogenical mecha-
nism (24,25). Indeed, the significant role of neutrophils in the 
promotion of ARdS-related alveolal damage was supported 
by a report in sepsis ARdS patients, where high neutrophil 
counts in bronchiolar lavage material harvested late in ARdS 
progression was associated with reduced patient survival (26). 
Hence, it has been proposed that the sulphone dapsone may 
show efficacy in COVID‑19 related ARDS, as the drug is 
highly and rapidly effective at inhibiting cytokine-mediated 
neutrophil chemotaxis and respiratory burst in a variety of 
therapeutic contexts (27). Efficacy of Dapsone in the treatment 
of Pneumocystis pneumonia suggests it will penetrate the lung 
tissue sufficiently to attenuate neutrophil activity. The haemo-
toxicity of the drug can be ameliorated with concomitant 
cimetidine administration (27,28).
Overall, the major clinical manifestations: sore throat, 
cough, breathing difficulties, malaise, fever, chills, diarrhea, 
generalized myalgia, drowsiness, dyspnea, and pneumonia are 
similar in SARS-coV2, MERS-coV, and SARS coV infec-
tions (29), but COVID‑19 differentiates itself from MERS and 
SARS in infectivity (R0), with much higher human-to-human 
transmission rates owing much to the fact that infectivity is 
not restricted to symptomatic patients (30); however, we can 
improve therapeutic strategies with inferences from structural 
comparisons of these viruses.
2. SARS‑CoV2 molecules and proposed antiviral drugs
SARS-coV2 consists of two types of molecules: RNA and 
proteins; RNA encodes for 27 viral proteins, of which 16 are 
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non‑structural proteins (nsps), and 11 are accessory and 
structural proteins. There are 4 major structural proteins: 
nucleocapsid protein (N), spike surface glycoprotein (S), matrix 
protein (M), and small envelope protein (E). The N‑protein 
binds to viral RNA, encloses it in a capsid and assists RNA 
synthesis and folding during viral replication; it also modifies 
host responses, cell cycle and gene translation, and after RNA 
replication it guides the viral membrane proteins for viral 
assembly. The S‑protein is essential for attachment and fusion 
of the virus to host cells (31).
Sequencing the SARS-coV2 genome in February 2020 (32) 
showed that phylogenetically it belongs to the genus 
Betacoronavirus, subgenus Sarbecovirus, and has closer 
genetic similarity to SARS-coV than MERS-coV. The 
genome consists of a single, positive-stranded RNA with 
~30 k (29,811) nucleotides; from these only 5 nucleotides were 
found to be different between SARS-coV2 and SARS-coV. 
Similar sequencing results (>99.9% similarity) were obtained 
by different teams on different patient samples (33,34): 
GenBank sequences MN988668, NC_045512, MN938384.1, 
MN975262.1, MN985325.1 and MN994468.1.
coronaviruses have the largest known RNA genomes and 
their RNA is transcribed via open reading frames (ORFs); 
this peculiarity increasing the efficacy of viral replication and 
mutagenesis, and making it more difficult to be eliminated by 
the immune system. The SARS‑CoV2 genome has 14 ORFs of 
different lengths; first ORF has ~10,000 nucleotides (~2/3 of 
viral RNA) and encodes nsps 1‑16, with the structural and 
accessory proteins being translated from the remainder 1/3 of 
RNA (35) (Fig. 1).
comparing the amino acid sequence of SARS-coV and 
SARS-coV2 reveals identical sequences in the envelope, 
matrix, nsp7, nsp13 and accessory proteins p6 and 8b, while 
nsp3 and nsp2 had 102 and 61 amino acid substitutions, 
respectively.
Importantly, orf8 and orf10 are present in SARS‑CoV2 but 
not in SARS-coV (36). The orf8 protein from SARS-coV2 
has no known functional domain or motif and is different 
from the orf8 or orf8b of SARS-coV, which does not have 
orf10 at all. However, ORF10 binds to heme and ORF8 to 
porphyrins (37); heme inactivation increases viral infectivity 
through inhibition of the host innate antiviral response (38) 
which relies on heme‑containing enzymes such as nitric oxide 
synthase (detailed below); also increases viral permeation of 
tissues via porphirin binding and tissue destruction (39).
The spike (S) protein of the new virus contains 1,273 amino 
acids; compared to SARS‑CoV it has 27 amino acid substitu-
tions, 8 in the heptad repeat domain, 6 in the RBd, and 4 in 
the S1 subunit, modifying two peptides which are antigens 
for SARS-coV (40). The binding energy between the viral 
S protein and host AcE2 receptor is higher in the new 
virus versus SARS‑CoV (‑50.6 kcal/mol vs. ‑78.6 kcal/mol) 
suggesting a more stable bond (41); at the same time the 
affinity of the S protein of the new virus for the ACE2 receptor 
is in the 15 nM range, which is about 10‑20 times higher than 
SARS-coV, an important factor for the differential infec-
tivity (42).
The S protein is a class I viral fusion protein like the 
influenza virus hemagglutinin (HA); SARS‑CoV2 also has an 
S1/S2 cleavage site which is recognizable by furin, a ubiqui-
tous cell protease. When similar modifications (insertion of 
a polybasic furin cleavage site) occur in the hemagglutinin 
proteins of avian and human influenza viruses, their virulence 
is greatly increased (43).
Functionally the S protein has a receptor-binding 
subunit (S1), an S2 fusion domain (S2), separated by a cleavage 
site (S1/S2) and another cleavage site (S2') located within S2. 
The multiple cleavage sites are activated by a wide variety of 
proteases from the host cell: cathepsins, serine proteases from 
the trypsin-like transmembrane serine protease family (TTSP), 
and furin-like proprotein convertases.
Both SARS-coV and SARS-coV2 need S protein 
priming through cleavage by a host cellular protease (trans-
membrane protease serine 2 ‑ TMPRSS2, TMPRSS11a, 
Table I. ARDS subphenotypes (data from Wilson and Calfee) (13).
 Hypoinflammatory Hyperinflammatory
Parameters ARdS ARdS
IL‑6, IL‑8, TNFr1 (plasma levels) Low High
Bicarbonate, cRP (plasma levels) High Low
Mortality Low High
Ventilator-free days High Low
PEEP (positive end‑expiratory pressure) associated Low High
with better 90-day mortality (ALVEOLI study)
Fluid strategy with better outcome for 90-day conservative Liberal administration
mortality (FACCT study) administration of fluids of fluids
Simvastatin administration has benefit on 28‑ and No  Yes
90-day survival (HARP-2)
Rosuvastatin administration has benefit on 90‑day No No
survival (HARP-2) 
ARdS, acute respiratory distress.
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hypoxanthine‑aminopterin‑thymidine, trypsin, elastase, 
cathepsin L) (44,45), and the cell surface from respiratory 
epithelial cells has abundant TMPRSS2 and trypsin-like 
protease (46). Interestingly, human airway epithelial cells 
can be infected by SARS-coV even when proteases from cell 
surface are absent (44), meaning that a cell fusion process 
used by SARS-coV involves endosomal membranes and a 
treatment which blocks only the cell surface proteases or the 
endosomal protease will not prevent, but only depress viral 
cell entry; however, a combination of two substances, camostat 
and EST, a cathespsin inhibitor effectively blocked the viral 
entry into cells.
SARS-coV2-infected cells aggregate to form syncy-
tiums; the S protein of SARS-coV2 can mediate a cell-cell 
syncytium formation without a proteolytic enzyme (trypsin), 
while SARS-coV S protein cannot; thus the membrane 
fusion capacity of SARS-coV2 is much higher than that of 
SARS-coV (46).
The S protein of both coronaviruses has another pecu-
liarity: its dependency on ca2+ (47). Significant cell membrane 
ordering prior to membrane fusion is needed, and it requires 
the presence of ca2+ ions because of the negatively charged 
residues in the fusion platform. consequently the entry of 
SARS-coV2 is highly dependent on the ca2+ concentration in 
its cell environment, and calcium chelators inhibit viral fusion 
and cell entry. Thus it was observed that SARS-coV entry is 
blocked by amiodarone, which blocks calcium channels in the 
endosome and lysosome (47).
The nsps perform essential functions in immune antago-
nism through formation of the viral replication complex and 
double membrane vesicles which shield the viral RNA, viral 
RNA proofreading, binding of nucleic acid and helicase 
activity (48).
Immunosuppressive functions of the SARS‑CoV2 proteins. 
Besides needing to ensure the entry of viral material into 
cells and subsequent replication, the viral proteins and RNA 
also need to evade the host immune system, and because the 
success of viral infection depends on the impairment of the 
host antiviral response, this aspect deserves special attention.
Airway epithelial cells are able to prevent viral infections 
through multiple mechanisms. The airway surface liquid (ASL) 
is secreted by the submucosal glands, goblet and club cells and 
mobilized by cilium cells, and contains the gel-forming mucins 
MUc5B and MUc5Ac, glycosaminoglycan keratin sulfate, 
and antimicrobial peptides and proteins (AMPs). ASL forms 
a pericilliary layer with volume, fluidity, pH and microbiome 
maintained in an optimal range for toxin elimination and the 
actions of AMPs, and facilitating mobilization of the innate 
immune response by macrophages, monocytes, dendritic cells, 
innate lymphoid cells, and γ/δ T cells. Finally an adaptive, 
specific immune response is triggered in response to antigens 
involving T and B lymphocytes, chemokines, cytokines and 
antigen-neutralizing IgAs (49).
After evading or overwhelming this first line of defense 
and entering host cells, the virus activates the cellular antiviral 
Figure 1. SARS‑CoV2 genome, translated proteins and some of their known pro‑viral actions.
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defenses effectuated by hundreds of proteins (cytokines, 
chemokines, host restriction factors) which block different 
steps in the viral replication and are activated by specific 
cell sensors/receptors. Interferons (IFNs) via IFN‑stimulated 
genes (ISGs) initiate innate and adaptive immune responses 
which alter host cell cycle, translation and apoptosis, virus 
entry, viral RNA availability, stability and translation, particle 
and budding (50).
Molecules involved in virus detection in the cytoplasm 
of host cells are: the retinoic acid-inducible gene-I (RIG-I), a 
RNA helicase with the respective cell receptors - RIG-I-like 
receptors (RLR); and the melanoma differentiation-associated 
protein 5 (MdA5), both of which have the same downstream 
effector: the mitochondrial antiviral signaling protein (MAVS). 
Besides RIG‑1 and MDA5, other cellular viral RNA sensors 
are known: the protein kinase RNA-activated (PkR), oligoad-
enylate synthetase (OAS), latent endoribonuclease (RnaseL), 
cyclic GMP‑AMP (cGAMP) synthase (cGAS) (51); PKR stops 
host cell translation and helps activate the NF-κB.
Early in infection the antiviral response is driven by the 
peroxisomal MAVS, while later the mitochondrial MAVS 
triggers an interferon (IFN)-dependent, sustained immune 
response. MAVS signaling ultimately results in NF-κB (and 
other pro‑inflammatory pathways) activation which translo-
cates to the nucleus and activates the transcription of genes 
encoding IFN-α/β, cytokines, many antiviral proteins, and 
RIG‑I/MDA5 in a positive feedback loop (52).
Following activation, IFN-α/β-type I IFNs are produced 
in and activate most cells, while type III IFN (IFN-λ) mostly 
mucosal cells; they activate very similar IFN-stimulated 
genes (ISGs). IFN signaling occurs very fast since it does 
not require new protein synthesis; all IFNs use the Janus 
kinase (JAk) - signal transducer and activator of transcrip-
tion (STAT) pathway. pdcs produce most of the IFN-α during 
an infection; IFN-γ bridges the innate and adaptive immune 
responses, helps regulate immune function, and is mostly 
secreted by activated T cells and natural killer (NK) cells (51).
TLRs from endosomes recognize viruses, while TLRs 
from cell membrane typically recognize bacteria. MAVS and 
the TLR adaptor MyD88 activate cell‑specific transcriptional 
pathways, with pro‑ or anti‑inflammatory profiles (ex macro-
phages vs. fibroblasts) (53).
All nucleated cells are thought to have RLR and PkR recep-
tors for viral nucleic acids, while toll-like receptors (TLRs) 
are present in myeloid dendritic cells (mDCs) ‑ TLR3/7 and 
plasmacytoid dendritic cells (pDC) TLR7/8, and also in endo-
somes of most cells (54).
TLR4 interacts with with the adaptor protein Myd88 
and activates the mitogen-activated protein kinase (MAPk) 
and the NF-κB signaling pathway. The c-Jun NH2-terminal 
kinases (JNk), the signal-regulated kinases (ERks), the 
p38 MAPks, are major MAPks with important roles in innate 
immunity (55).
SARS blocks antiviral defenses and the IFN production 
in multiple ways, at multiple sites, many involving RIG-I and 
MAVS (50): i) after transcription the coronaviral dsRNA is 
protected from detection by storage in double-membrane 
vesicles; ii) M protein of SARS virus localizes in membranes 
associated with the Golgi complex and binds to the host RIG‑I, 
thus impeding activation of MAVS; iii) ORF3b and ORF6 
move to the mitochondria and block the interaction between 
RIG-I and MAVS to block IFN induction; iv) the papain-like 
protease (PlPro) removes ubiquitin from RIG-I and down-
regulates type-I IFN response; v) cytoskeleton perturbations 
in mitochondria, with modification of the mitochondrial 
membrane potential and impairment of MAVS activity; 
vi) blocking IFN-β production by de-ubiquitination (dUB) of 
RIG‑1 and other viral sensors and effectors (56).
Microarrays helped identify the proteins through which 
viral particles can antagonize host immune responses: 
13 proteins were inhibitors of MAVS (LGP2, A20, SMURF2, 
etc.) 14 for RIG‑1 (USP3, ARL16 and RNF122) and 6 for 
MDA5 (USP3, ARL5B, TRIM59); RNF125 inhibited RIG‑1, 
MDA5 and MAVS (57).
Proposed therapeutic interventions. The current therapeutic 
interventions for COVID‑19 (18) are derived from SARS treat-
ments; the first drugs shown in 2005 to be effective in vitro 
for SARS, both pre‑ and post‑exposure, are chloroquine and 
hydroxychloroquine; since they were extensively studied and 
shown to exert pleiotropic antiviral actions (58). Chloroquine 
is a weakly basic substance and upon entering cells it is 
protonated and concentrated in acidic organelles: lysosomes, 
Golgi vesicles and endosomes; the subsequent increase in 
endosomal pH interferes with the terminal glycosilation of 
the AcE2 receptor. Besides inhibiting the S protein-induced 
viral fusion (59), and the PlPro protease (60) chloroquine 
can benefit patients with porphirin extravasation (Fig. 2) by 
preventing orf1ab, orf3a, orf10 attack on hemoglobin (37) with 
porphirin formation.
Protease inhibitors target viral nsps needed for its replica-
tion, such as the RNA-dependent RNA polymerase (RdRp) 
inhibited by ribavirin (which also inhibits viral mRNA 
capping); the 3c-like protease (3cLpro) is inhibited by the 
lopinavir-ritonavir combination (48), which seems to have 
better results compared to ribavirin, which was associated 
with anemia, hypoxia and increased risk of death in SARS 
patients (61).
FdA-approved drugs and agents re-purposed for 
COVID‑19, such as ribavirin, IFNs and corticosteroids, were 
shown, however, to be ineffective especially in severe coV 
infections (48); recent data on SARS-coV2 suggest that more 
specific and efficacious treatments can be administered to 
COVID‑19 patients; Table II summarizes such proposed 
FdA-approved drugs and Fig. 3 offers a graphic presentation.
Among COVID‑19 proposed drugs already approved for 
other pathologies, GR 127935, a known potent entry inhibitor 
of Ebola and Marburg viruses, binds the SARS-coV-2 receptor 
ACE2 and also is a selective 5‑HT1B/1D receptor antagonist, 
making it useful in patients with hypotension and tachyar-
rhythmia, when administration of vasopressors is questionable.
Agents that bind the SARS-coV-2 spike protein and are 
known to reduce lung inflammation, include GSK1838705A, 
BMS195614, GSK1838705A, which inhibit the insulin like 
growth factor‑1 receptor and are used in cancer.
For blocking the AcE2 receptor, three FdA-approved 
drugs are proposed: TNP, an inhibitor of tyrosine kinase, 
IP6k and Akt pathways, which can also shown to inhibit 
MERS infection; eptifibatide acetate, an inhibitor of 
platelet aggregation already tested in septic shock; and the 
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Abelson (Abl) kinase inhibitor GNF5, known to inhibit repli-
cation of dengue virus, which deserves further attention. It 
was shown that Abl2, but not Abl1 is necessary for replication 
of SARS/MERS CoV (66) as the virion and endosomal 
membranes fuse via a cathepsin L-dependent mechanism; 
the Abl2 kinase inhibitors GNF5/GNF2/imatinib inhibit the 
Figure 2. Severe COVID‑19, interstitial hemorrhage, porphyria, necrosis. (A) Bullous porphyria and necrosis in literature (39). (B) Our own experience.
Figure 3. Antivirals and their actions.
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fusion of the viral and endosomal membrane, an early stage of 
viral infection. GNF5/GNF2/imatinib also inhibit the forma-
tion of cell syncitia before the hemifusion step, effectively 
blocking membrane fusion and viral entry (67).
Finally, 3 drugs deserve special attention for COVID‑19 
treatment: KT185 and KT203 which bind the S protein and 
are potent, selective inhibitors of a/b‑hydrolase domain 
containing 6 (ABHd6), a transmembrane serine which 
hydrolases the endogenous cannabinoid 2-arachidonoyl-
glycerol (2-AG), and more importantly decrease macrophage 
activation.
The third drug is probably the best viral fusion inhibitor, 
RS 504393, which can bind both the SARS-coV-2 S protein 
and its receptor AcE2 and is used for treating lung injury 
and bronchial wall thickening; moreover, it is also a selective 
antagonist of the monocyte chemoattractant protein‑1 (MCP‑1) 
receptor ccR2, blocks the upregulation of pronociceptive, 
pro‑inflammatory interleukins IL‑1β, IL‑18, IL‑6, and as such 
are very useful for decreasing the ‘cytokine storm’ and the 
associated neuropathic pain (patients hypersensitive to touch).
Besides FdA-approved drugs, a variety of natural 
compounds have been investigated for their antiviral actions 
Table II. FdA-approved drugs with SARS-coV2 antiviral actions.
 Viral molecule inhibited;  Method and/or software used for testing
Substance analyzed (Ref.) mechanism FdA approved drugs
Hydroxychloroquine and Spike (S) Protein - binding  Virtualized quantum mechanical modeling
azithromycin (59) motifs of AcE2 receptor;
Eptifibatide acetate, ACE2 receptor protein High‑throughput virtual screening used to
TNP, GNF5, GR 127935, of host cells investigate LOPAC library drugs
RS504393 (62) binding site
KT185, KT203 S‑protein (RBD of spike protein) Software: PyRx, Open Babel, AutoDock Vina, 
GSK1838705A, binding site PyMol, GROMACS; online resources
BMS195614, RS504393 (62) anti‑inflammatory SWISS MODEL, HADDOCK, RCSB PDB,
  NcBI, Procheck at RcSB validation server,
  ProSA-web, SAVES-Verify3d server
Darunavir, Nelfinavir, Protease: Structure‑based drug repositioning
Saquinavir, Rosuvastatin (63) Mpro, central site
Montelukast, Fexofenadine (63) Protease: Structure-based drug repositioning
 Mpro, terminal site 
chloroquine, Protease: Homology model of the protease based on
formoterol, 16 other FDA‑ papain‑like protease SARS‑coronavirus PLpro structure; drugs
approved drugs (60) (PLpro) docked in S3/S4 pockets of active site
Remdesivir (‑13.1 KJ/mol) Protease Connectivity map and the docking configurations used
cloperastine (‑10.4) 3CLpro (PDB ID 6LU7) to simulate the docking bonding energy between
vigabatrin (‑10.2)  antiviral and the respective protease in KJ/mol
methotrexate (‑6.9)  
Remdesivir (‑18.6 KJ/mol) Protease Used PyRx for loading and visualising the SDF files for
vigabatrin (‑12.1) 6Y84 ‑ main protease with the ligands and the AutoDock Vina tool for testing the
cloperastine (‑10.1) nicer‑ unliganded active site docking on two target proteins 6LU7 and 6Y84 from PDB
goline (-9.0) phenazo-
pyridine (-8.4) (64)
Pemirolast (65) Protease; RNA Replicase Using COVID‑19 Docking Server
 inhibitor 
Chloroquine (37) Accessory proteins Simulated molecular docking of viral proteins with
 prevents binding of orf1ab, human heme or porphyrins with (LibDock tool) of
 ORF3a, ORF10 to heme, Discovery‑Studio 2016
 ORF8, surface
 glycoproteins to porphyrins 
Favipiravir (37) Accessory proteins: Simulated molecular docking of viral proteins with
 inhibits binding of E protein, human heme or porphyrins with (Libdock tool) of
 ORF7a to porphyrin, prevent Discovery‑Studio 2016
 virus entering host cells 
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on SARS-coV2, one advantage being that some plants 
contain more than one active ingredient (65); in the case 
of Nigella sativa its main active substances, nigellidine 
and α-Hederin compare positively to either chloroquine or 
hydroxychloroquine based on their binding energy with viral 
proteases (68), more information is given in Table III.
Local treatment and IFNs. Based on the observation that the 
host IFN response is delayed in coV infections, with subse-
quent over-activation of neutrophils in the lung and vascular 
leakage (54), IFN-stimulating substances administered by 
inhalation showed efficacy against SARS and MERS in vitro 
and in vivo. Inhaled substances have the advantage of lower 
volume of distribution (ASL has a volume of 20-30 ml) and 
can act early in cOV infection during the viral fusion process, 
inhibiting the binding of its S protein to the host receptor (71).
One such substance is polyI:c, a TLR3 agonist shown to 
induce differentiation of mDC, promote Th1 activation with 
IL‑12 and type I IFN production, the activation of the innate 
immune response and reversing the PGd2 effects in the 
lungs (72,73). A shortcoming of the polyI:C may be its require-
ment for either RIG‑1 or MDA5 activity, which are known to 
be inactivated by coronaviruses and render polyI:c ineffective 
post‑infection, limiting it to a prevention drug (74).
A very potent inhibitor of coV fusion is nona-L-arginine 
with high affinity for furin (effective at concentrations of 
40 nM); hexa‑ and hepta‑peptides of the basic aminoacids 
arginine and lysine also showed excellent inhibition of viral 
fusion (75).
Another intranasal‑administered peptide, EK1, which 
contains the heptad-repeat HR2 from the binding motif of the 
S protein has inhibited infection by many human coronavi-
ruses (46); its administration in mice reduced lung viral titers 
by 1,000‑fold 2014 (76) and its lipidation, EK1C4, resulted in 
much greater potency, inhibiting the cell-cell fusion mediated 
by S protein with Ic50 of 4.3 nM; its protective effect mani-
fested half an hour after and 6 hours before exposure to 
coronavirus (46).
IFN can also be administered directly to patients via inha-
lations, however, affinity amino acids have showed limited 
benefits depending on the timing of administration and 
prompts further analysis of IFN actions.
Similarly to the neutrophilia and lymphopenia observed 
in severe COVID‑19 patients, fatal SARS infection is associ-
ated with high IFN and ISGs expression and low T cell and 
antibody activity, while viral clearance needs increased T cell 
responses (25).
The immune response of coV patients is imbalanced, 
with over-stimulation of the monocyte-macrophage line and 
decreased T cell activation; while early administration of 
IFN‑1 has protective effects, in later stages administration of 
IFN, with the possible exception of IFN‑γ, is associated with 
increased neutrophil infiltration in the lungs. This is due to 
the selective activation of ISGs in macrophages, but not in 
B or T cells, since signaling in these cells requires the myeloid 
differentiation factor 88 (Myd88), a key molecule used in 
all TLR signaling pathways of adaptive immunity except for 
TLR3 which is present in all endosomes (77).
In animal models of lethal cOV infection, the immu-
nopathological events are mostly IFN-I-dependent and 
independent of viral replication; IFN-α/β receptor (IFNAR) 
receptor ablation or neutrophil depletion avoided lethal infec-
tion but did not affect the viral load. TNF inhibition improved 
lymphopenia, which is not unexpected since IFN‑I sensitizes 
T cells to apoptosis.
It was shown that an important role in modulating the 
inflammatory response is played by two proteins containing the 
Toll or interleukin (IL)‑1 receptor (TIR): MyD88 and the TIR 
domain‑containing adaptor‑inducing interferon (TRIF) (78). 
For controlling inflammation both MyD88 and TRIF proteins 
Table III. Natural compounds with antiviral actions.
 Viral molecule inhibited;  
Substance analyzed (Ref.) mechanism Method and/or software used for testing
Anisotine and vasicoline of Protease; Using COVID‑19 Docking Server
Justicia adhatoda (65) RNA Replicase 
 inhibitor 
Phycocyanobilin, Riboflavin, Cyanidin, Protease (Mpro); COVID‑19 Docking Server to 
daidzein, Genistein (69) RNA Replicase inhibit Mpro and RdRp
 inhibitors 
Curcumin (70) Protease Structure of metabolite and COVID_19 protease
 inhibitor from Pubchem and Protein data Bank (PdB);
  molecular docking by MVd (Molegro Virtual docker)
For 6LU7: Nigellidine ‑6.29 Kcal/mol; Proteases Docking of compounds from Nigella sativa
chloroquine ‑6.29; OH‑chloroquine ‑5.57; (3CLpro and and drugs performed with Molecular Operating
favipiravir -4.23; For 2GTB:  Mpro) Environment software (MOE)
α‑Hederin ‑6.50 kcal/mol;  6LU7 and 2GTB
chloroquine ‑6.20; OH‑chloroquine ‑5.51;  inhibitors
favipiravir ‑4.12 (68)
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are required, since the release of the anti‑inflammatory IL10, 
IL19, endothelial lipase, metalloproteinase inhibitor 1 (Timp1) 
and plasminogen activator inhibitor 1 (Serpin1) is prevented in 
the absence of either one, resulting in excessive pro‑inflamma-
tory modulation.
during early coV replication in non-lethal models, pdcs 
are the major IFN-I producers, and pdcs sense coronaviral 
RNA via TLR7 within endosomes (54). The same author 
shows that the coronavirus endonuclease (EndoU) from 
nsp 15 has a key role in preventing early induction of innate 
responses, by removing the viral dsRNA that would otherwise 
trigger host cell dsRNA responses, including IFN, PkR and 
OAS/RNase L, and delaying the viral RNA cytoplasmic 
sensing mediated by MdA5.
during early stages of SARS infection, IFN-γ presence 
is associated with viral clearance and infection resolution; 
IFN-γ is synthesized mainly by activated T cells and natural 
killer (NK) cells (79). IFN‑γ (type II) and IFN-α/β (type I) 
have synergistic actions; given alone neither inhibits viral 
replication, but administration of both inhibited viral replica-
tion by 3000-fold at 24 h, with stronger inhibition at 48 and 
72 h.
Oligonucleotide arrays were used to study the ISGs regu-
lated by IFNs; all IFNs induced complement component C1r, 
IFN-induced nuclear phosphoprotein, vascular endothelial 
growth factor (VEGF)-related protein (VRP or VEGF-c), 
and phospholipid scramblase, an apoptosis promoter; its 
levels increased 8-fold by IFN-α, 10‑fold by IFN‑β, and 
3-fold by IFN-γ (80). Additionally each IFN preferentially 
induced specific molecules: IFN‑α, somatic cytochrome c; 
hepatitis C‑associated p44; pyridoxal kinase; and lysosomal 
acid lipase (LIPA); IFN-β, clathrin-like protein, PkR, 
hypoxia‑inducible factor‑1 (HIF‑1α) which regulates apop-
tosis and cell response to hypoxia via expression of VEGF, 
p53, p21; IFN‑γ, mitochondrial 3-ketoacyl-coA thiolase; 
poly (AdP-ribose) polymerase; proton-ATPase-like protein.
Both type I and type II IFNs increase expres-
sion of the cH25H gene which codes for the enzyme 
Cholesterol‑25‑hydroxylase, which converts cholesterol into 
25‑hydroxycholesterol (25HC) (50), an oxysterol with antiviral 
effects via alteration of membrane properties, inhibition of 
sterol biosynthesis and prenylation (priming) of virus and host 
proteins. However, 25Hc production by macrophages also has 
a central role in regulating the immune system, and at nM 
concentrations it suppresses the IL-2 mediated proliferation of 
B cells and inhibits IgA production (81).
Another possible pathological modification induced by the 
coV in susceptible patients is the activation of alternatively 
activated macrophages, M2, which normally have anti‑inflam-
matory actions and are involved in the wound-healing 
processes (82), but were also found in the lungs of mice lacking 
STAT1 signaling pathway (STAT1 knockouts), which after the 
SARS-coV infection, had an increased number of M2 macro-
phages in their lungs, activated via the STAT6 pathway, and 
developed pulmonary fibrosis (83).
The modifications induced by the SARS‑Cov infection in 
host cells were also investigated via a library screen of small 
interfering RNA (siRNA) targeting the human kinome (84). 
Besides the expected activation of pro‑inflammatory pathways 
(production of NO and ROS in macrophages, IL-2, IL-6, 
IL‑8 and IL‑17) there was also an increase in the metabolic 
pathways of complex lipids (inositol phosphate, nicotinate, 
nicotinamide), intermediates needed in SARS-coV infection 
and probably linked to prenylation. The strongest proviral 
activation was seen in the β2 subunit of the coatomer protein 
complex (COPB2) followed by inositol hexaphosphate 
kinase 1 (IHPK1); abelson kinase 1 (ABI1); diacylglycerol 
kinase epsilon (dGkE); cyclin-dependent kinase 5 regulator 
(cdk5R2); protein kinase c ι (PRkci). Among antiviral 
molecules were found the diacylglycerol kinase δ (dGkd), 
the double-stranded RNA-activated protein kinase (PkR); 
cyclin-dependent kinase 6 (cdk6) and most MAPks with 
the exception of MAP3K11, which is weakly proviral; 
ABl1 inhibitors and molecules acting on lipidic and glucidic 
metabolism are thus important.
Another factor influencing IFN actions is the hemo-
globin β-chain which was shown to stimulate IFN-β production 
via RIG‑1, including potentiating of RIG‑I ubiquitination; 
hemoglobin is present in lung, kidney, peripheral blood mono-
nuclear and other cell lines (38,85), and SARS-coV2 nsps can 
bind to and degrade hemoglobin (37).
Indoleamine 2,3‑dioxygenase (IDO), stimulated by 
IFN-γ and inhibited by TLR activation and allergens plays 
an important role in immune suppression (normally prevents 
hyper‑inflammation and autoimmunity) by inhibiting T cell 
activation and polyclonal proliferation of T cells, mostly 
through degradation of tryptophan and kynurenines; its 
role in SARS‑CoV2 infection was not explored but likely is 
important (86). Activation of IdO is strictly dependent on 
prior expression of Arginase 1 and the resulting polyamines, 
with immunosuppressive actions (87); while NO is an IDO 
inhibitor; the role of IdO in the SARS-coV2 infection and its 
immune evasion has not yet been explored.
The  data above confirm that in severe CoV infection the 
host immune system is mounting an imbalanced response to 
infection which powerfully favors neutrophils/macrophages 
and inhibits the adaptive cellular response; early events 
include hindered pdcs activities and over-activation of 
macrophages with induction of IFN‑I expression and autocrine 
over‑stimulation; this may be due to 25‑hydroxycholesterol or 
IdO overactivation, Myd88 inactivation by the virus, hemo-
globin degradation and/or simultaneous actions of other viral 
molecules (EndoU).
However, it is possible that the delayed IFN response 
followed by neutrophil over-activation is simply due to the lack 
of activation in the early stage of infection of the peroxisomal 
MAVS necessary for early IFN production (52), and this obser-
vation gains more weight as peroxisome function declines 
significantly in tandem with cellular senescence, advancing 
age, and age‑related co‑morbidities (88). Peroxisome senes-
cence is associated with dramatic changes in their protein 
import capabilities, functional integrity, ability to process 
ROS, regulation of growth and division of other organelles, 
decreased ability to oxidize fatty acids, accumulation of free 
fatty acids and diacylglycerol, followed by reorganization of 
protein kinase c (Pkc) signalling (89).
This fact is related to the important metabolic functions 
of peroxisomes, which have >50 enzymes in their matrix 
performing critical metabolic functions besides produc-
tion and degradation of H2O2 including fatty acid oxidation, 
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synthesis of specialized lipids, including anti‑inflammatory 
docohexaenoic acid and degradation of pro‑inflammatory 
leukotrienes and recently it was shown that multiple viruses 
interfere with antiviral signaling dependent on peroxisomes, 
examples being the accessory protein Vpu of HIV‑1 which 
annihilates peroxisomes (90), the VP16 protein of HSV‑1 
which blocks the peroxisomal MAVS (91), also the hepatitis C 
virus protein NS3-4A, the capsid of the dengue and West Nile 
virus, and the vMIA protein of cytomegalovirus (92).
Peroxisomal MAVS stimulates ISGs via IRF1 and IRF3 in 
an IFN-independent manner and does not induce IFN produc-
tion in macrophages, which is dependent on mitochondrial 
MAVS. Interestingly, cells lacking either peroxisomal or mito-
chondrial MAVS had an unusual biphasic behavior, restricting 
viral replication in the first 24 h, but not at 72 h, and showing 
that both organelles are necessary for viral clearance (53). The 
functional status of peroxisomes can be correlated both with 
age and the severity of SARS-cov2 infection, and is impaired 
by poor oxidative status, low cellular pH (acidosis) and/or 
hypoxia which is also seen in patients with chronic pathologies 
or genetic deficiencies.
pH‑dependent viral actions. At the surface of the respira-
tory epithelium low pH favors viral entry and replication by 
impairing the actions of the AMPs from the airway surface 
liquid (ASL), which have pH-sensitive antimicrobial functions, 
with the pH of ASL being actively regulated by bicarbonate 
transport (49); another pH-lowering viral activity is the forma-
tion of cell syncytiums. Lower intracellular pH favors the 
activity of the proteases needed for viral replication, decreases 
the mitochondrial membrane potential and inactivates MAVS, 
which is essential for IFN and NFκB activation and produc-
tion of antiviral protein switches. In addition, low pH promotes 
oxidative phosphorylation to anaerobic glycolysis with 
increased mitochondrial ROS production via related cellular 
pathways (93).
The modifications in the cellular redox state, ionic balance 
and pH which are simultaneous with the actions of specific 
molecules in a pathway are not often measured or considered 
during lab experiments, but in the context of dual or multiple 
regulators they may have important consequences, one such 
example being the effect of hemoglobin (Hb) on IFN produc-
tion (85). While exerting a direct inhibitory effect on MDA5 
which inhibits IFN production, Hb also modifies a cell redox 
state, promotes the RIG-I pathway and stimulates IFN produc-
tion; the increase in ROS by Hb is stimulated only by the 
microbial and not by the host protease.
Additionally, the infectivity of coV and other enveloped 
viruses is known to be impaired by an increase in endosomal 
pH in a dose-dependent manner; mild bases such as lipophilic 
amines or amphiphilic drugs with a tertiary amino group can 
accumulate in acidic organelles via protonation, where they 
neutralize internal pH, alter the properties of the adjacent 
membranes and inhibit multiple processes occurring in the 
respective compartment (94); this was also observed with 
administration of bafilomycin or ammonium chloride (NH4Cl) 
in cell cultures at 5 mM concentrations (58,72,95). In case of 
coV the elevated endosomal pH blocks the cysteine proteases 
cathepsin B and L (CatB/L) (45) and inhibits the S protein 
entry into host cells. Furthermore, NH4cl and chloroquine 
(also a weak base) impair the glycosylation of AcE2, an addi-
tional mechanism for blocking viral fusion.
The pH-dependent fusion of various viruses endocytosed 
into host cells by non-coated vesicles (caveolas) or in associa-
tion with clathrin is well-documented (96); additionally coV 
and influenza viruses can fuse with host cell membranes 
via anchoring cell receptors and internalization in the lipid 
bi-layer, a process blocked by constituent hydrolaze cH25H, 
methyl-β‑cyclodextrin, a cholesterol‑sequestering drug, simv-
astatin and possibly other lipophilic statins.
Low pH is affecting essential aspects of the native immune 
response ‑ neutrophil activation, chemotaxis, production of 
ROS, NO and phagocytosis, apoptosis, cytokine production, 
activation of transcription factors by binding to dNA, and 
also decrease of lymphocyte function, lymphokine secre-
tion and activation, while hypoxia is potentiating these 
actions (97‑101); acidosis is associated with increased need 
for intensive care and hospitalization (102). In addition, a low 
extra‑ and intra‑cellular pH not only favors viral infection, but 
also impedes the antiviral action of known medication.
pH modifies the activity of antiviral medications. Many 
proteins undergo conformational changes of their tertiary and 
quaternary structure induced by ionic changes (ca2+, H+, Fe2+ 
and Mn+) and pH modifications. Such modifications are docu-
mented for the main protease (Mpro) of SARS-coV2 during its 
binding to protease inhibitors at pH 4.0-8.0, and it was shown 
that they were pH-dependent, with different binding energy 
(stability of protein complex) and specific bonding type/atom 
interaction (103).
Small modifications in pH can have critical consequences 
as was shown with arbidol, a broad-spectrum antiviral which 
binds to the influenza virus haemagglutinin (HA), induce a 
0.2 unit pH modification and blocks viral fusion; consequently 
some influenza strains developed a HA which disrupted the 
drug‑HA bond with loss of medication effectiveness (104).
More aspects of pH modifications in viral infections are 
discussed below; re-establishing physiological pH levels 
(7.35‑7.45) is an important therapeutic consideration in 
ALI/ARDS.
Genetic and translational factors involved in severe 
COVID‑19. An important question is whether the host genetic 
factors significantly impact the immune functions and the 
host answer to viral infection, as it was found that individual 
variations exist in expression of RIG‑1 and other antiviral 
molecules (57).
Studying the bronchoalveolar lavage fluids from ARDS 
patients by proteomic analysis during the initial 4 days of care, 
survivors and non-survivors showed differences: non-survivors 
had decreased expression of proteins involved in immune acti-
vation, coagulation, iron metabolism, and increased protein 
expression of glycolysis and collagen pathways (105).
Also, an association was found between four SNPs and 
ARDS patients: rs78142040 of ARSD ‑ an arylsulfatase 
gene involved in sphingolipid metabolism and associated 
with 60‑day mortality; rs9605146 in XKR3 gene affecting 
membrane transport and red cells, neuromuscular and 
central nervous systems, was associated with susceptibility to 
ARDS; rs3848719 of ZNF335, zinc finger protein regulating 
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lymphoblast proliferation, was associated with increased 
ARdS severity (APAcHE II score); nicotinamide phosphori-
bosyltransferase (NAMPT) with the ‑1535T allele associated 
with decreased susceptibility to ARDS, and the ‑1001G variant 
with higher susceptibility to ARdS and mortality in a 
caucasian population; other pathways showing differential 
activation in ARdS patients were T lymphocyte signalling, 
calcium-induced apoptosis of T lymphocytes, B-cell develop-
ment, and autoimmune thyroid disease (106).
Other genes associated with the pulmonary injury type 
of ARDS are POPDC3 (expressed in cardiac and skeletal 
muscle, role in glioma and muscular dystrophy), PdE4B 
(phosphodiesterase), ABCC1 (organic anion transporter 
of oxidized glutatione, cysteinyl leukotrienes and antiviral 
drugs), and TNFRS11 (TNF receptor superfamily member 11) 
the rs1190286 allele of POPDC3 is associated with decreased 
ARDS risk (107).
Using bioinformatic analysis for genetic associations 
with ARDS, a total of 201 genes were found predominantly 
involved in pathways modulating inflammation, especially 
linked to innate immunity, reactive oxygen species, and endo-
thelial vascular signaling (108); it is worth noting that all these 
pathways are modulated by NOS.
ACE2, RAS and ACE inhibitors. First genetic markers 
analyzed as risk factors for ARdS pathogenesis were found 
in 2002 to be correlated with AcE polymorphism, with the 
D allele increasing its actions (109). The frequency of the 
DD genotype was significantly increased in the ARDS group, 
suggesting a role for the renin-angiotensin system in ARdS 
development. A 2004 study in a small Vietnamese popula-
tion with SARS found an increase frequency of d allele in 
patients with hypoxia (n=22) versus no hypoxia (n=22) (110). 
However, a larger study (n=168) evaluated the influence of 
ACE I/D polymorphism on SARS‑CoV infection susceptibility 
and development of ARdS in a chinese population and found 
no association between the frequency of the d allele and pres-
ence of infection or severe disease; the only factors associated 
with requirement of intensive care was age and male sex (111).
Measuring serial AcE levels in a small number of ARdS 
patients (n=36) revealed that during the first 24 h the ACE levels 
were normal or decreased, with no difference between septic 
and aseptic ARdS, and after an initial decrease during the 
first 96 h ACE levels normalized by day 7; persisting low 
AcE levels tended to be associated with ARdS aggravation 
and fibrosis (112).
AcE2 is the main host receptor used by SARS-coV2, and 
together with its homologue ACE, also a non‑specific protease, 
modulate the activity of RAS, with AcE2 inactivating 
angiotensin II (AngII). In animal models, administration 
of recombinant AcE2 protects mice from lung injury and 
ACE‑deficient mice had much better outcome in acute lung 
injury (113). Also in animal models with acute inflamma-
tion it was shown that the renin angiotensin system (RAS) 
regulates neutrophil influx and pre‑treatment of mice with 
the RAS inhibitor enalapril and losartan decreased lung 
neutrophil infiltration, concomitant with bradykinin increase 
and angiotensin II decrease; agonists of bradykinin receptor 
also inhibited neutrophil chemotaxis induced by IL‑8 and 
pulmonary recruitment of neutrophils (114).
Angiotensin II activates NF-κB in monocytes with proin-
flammatory effects, and RAS inhibitors also decrease NF‑κB 
activation and neutrophil chemotaxis (115). Moreover, angio-
tensin converting enzyme (AcE) affects pulmonary vascular 
tone and permeability, epithelial cell apoptosis, and lung 
fibrosis via fibroblast activation so that RAS inhibitors may be 
beneficial in ARDS.
AcE2 inactivates AngII and was shown to protect mice 
from sepsis-induced ALI, by downregulating RAS which is 
involved in pulmonary hypertension and pulmonary fibrosis; 
ACE2 expression increases after IFN‑I administration. 
SARS-coV infection produces a rapid downregulation of 
ACE2 expression at cell surface, ACE2 protein levels and 
RNA expression (83,116).
Another observation is that AcE inhibitors increase 
levels of the peptide Ang‑(1‑7), which inhibits allergic 
inflammation by suppressing ERK‑ and NF‑κB-dependent 
pathways (117,118).
Translating data from animal models to clinical practice 
shows sometimes important differences, and we have contra-
dicting results in clinical trials involving RAS and ARdS. 
A South Korean study with 182 patients (115) showed that 
mechanically ventilated patients on RAS inhibitors had better 
survival rates at 30 days than patients not receiving them; 
however at 90 days there was no significant difference in 
mortality between the 2 groups, and patients on RAS inhibitor 
required longer IcU stay and mechanical ventilation.
More studies are needed to inform decisions on the use of 
RAS inhibitors in coV infected patients; we should note that 
AcE inhibitors increase bradykinin levels, responsible for the 
associated cough and angio-edema and also a potent vasode-
pressor (119), restricting their use in patients with COVID‑19 
ARdS and hypotension. The risk for bradykinin-mediated 
adverse reactions was found to be linked to the levels of 
aminopeptidase P, which catabolizes bradykinin and was 
significantly lower in hypertensive patients with a history 
of angio‑oedema during ACE inhibitor treatment (120); the 
aminopeptidase N is also a receptor for some strains of coro-
naviruses (121).
3. The combination of arginine‑ascorbate
There is ample data suggesting that the severity of the 
COVID‑19 is less related to the viral replication itself than 
to the host responses to the infection: delayed IFN produc-
tion, increased neutrophils and cytokines in the lung creating 
a pro-inflammatory, pro-apoptotic milieu, combined with 
lymphopenia, acidosis, coagulation and vascular endothe-
lium modifications and defective tissue repair with fibrosis 
in the lungs. Most treatments are focused on blocking viral 
replication, however, in fatal cases irreversible changes and 
deterioration occur even though viral replication is essentially 
blocked. Therapeutic interventions which combine agents 
for pleiotropic actions rather than single agents acting on 
well-defined pathways are more likely to improve patient 
outcomes.
Analyzing genes with modified expression in ARDS 
evidenced 201 genes, predominantly from pathways modu-
lating inflammation, innate immunity, reactive oxygen species, 
and endothelial vascular signaling (108); all these pathways 
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are modulated by NO generated from arginine, the only physi-
ological substrate for NO (122).
Arginine‑ascorbate has several important benefits in CoV 
infection: firstly, direct antiviral actions, secondly, improve-
ment of leukocyte function and number, especially important 
in patients with neutrophilia and lymphopenia and finally it 
provides essential components and stimulates the mechanisms 
of tissue repair.
a) Antiviral actions. during the 2003 SARS epidemic 
medicinal NO gas, a mixture of 0.8% NO and 99.2% N2 was 
administered by keyaerts et al (123) and followed by prompt 
improvement in oxygenation and sustained patient benefit; 
following-up on this observation it was shown that NO donor 
compounds inhibited SARS-coV replication in vitro, a 
finding replicated by another team who also observed 
that besides S-nitroso-N-acetylpenicillamine (SNAP), 
IFN also inhibited SARS-coV replication in vitro (124), 
confirming results obtained by another team who showed 
that IFN stimulates iNOS and NO production for prompt 
antiviral action (125).
Interestingly, IFN-γ stimulates NO production, and 
inhibition of NOS in mice resulted in conversion of a 
resolving infection by the ectromelia virus into fulminant 
mousepox (126).
NO production from arginine by the inducible NO 
synthase (iNOS) was shown to be essential for native immune 
responses in many infections and arginine availability is a crit-
ical factor for host resistance to infection (122). NO can pass 
through membranes, unlike complement and antibody, and 
is especially useful in syncytia, it can act on multiple targets 
increasing efficacy and preventing developing of resistance, 
and do not require recognition of infected cell by the immune 
system, which can be limited by pathogens or tissue‑specific 
differences (127).
Reducing arginine availability either by nutrient depriva-
tion or by specific pathogens significantly blunts the immune 
response, the former via impaired TLR4/MAPK pathway 
signalling, the latter by inducing arginase 1 via other TLRs 
in macrophages in an autocrine-paracrine manner involving 
cytokines, an immune evasion mechanism shown with myco-
bacteria (122) and probably also in SARS‑CoV2 infection.
Arginine also directly stimulates transcription/translation 
of the iNOS gene leading to de novo NOS protein synthesis, 
and this sheds light on the ‘arginine paradox’ where intracel-
lular NO production is directly related to the extracellular 
arginine concentration even though endogenous synthesis of 
arginine provides approximately half of the arginine needed by 
cells (128). To ensure the increased need for intracellular argi-
nine, the cationic amino acid transporter cAT2B is induced 
by IFN-γ, which is stimulated by ascorbate (129). Reciprocally, 
the pH buffering action of arginine is increasing the cellular 
uptake of ascorbate by improving the activity of the cellular 
transporter of ascorbate, SVcT2, which has a pH optimum 
of 7.5 and is reduced to ~50% when pH is 5.5 (130).
Ascorbate is actively accumulated in phagocytic cells 
where its concentration is 70‑100 times higher than in plasma; 
it enhances chemotaxis, ROS generation, phagocytosis and 
viral clearance, important for minimising necrosis and tissue 
damage (131).
Ascorbate stimulates the synthesis and actions of antiviral 
NO indirectly in multiple ways, one via IFN-γ stimula-
tion (132), another via inhibition of HIF‑1α and correction 
of hypoxia, which significantly inhibits the availability of 
intracellular arginine and NO production (133); and also 
by synergizing with the apoptotic effects of NO (134) in 
virus-infected cells, and thus inhibiting viral replication. 
It is also important to note that all three of NOS as well as 
IDO (135) are heme‑containing proteins which require ascor-
bate or another intracellular reducing agent for their activation. 
In this context, the observation that three accessory proteins of 
SARS‑CoV2 ‑ orf1ab, ORF3a, ORF10 ‑ bind to heme followed 
by Fe inactivation and sequestration (37) deserve to be further 
investigated for specific anti‑NOS and other IDO activities.
In the case of SARS-coV2 infection which directly antag-
onizes NO production, arginine provides both the substrate 
for iNOS and activates its synthesis; together with ascorbate, 
which is necessary for iNOS activation, it prepares a new 
functional enzyme necessary for NO production.
b) Improving lymphocyte function and number. Lymphopenia 
is present in a significant number of severe COVID‑19 
patients (9) and its causes are strongly linked to arginine and 
ascorbate deficiencies.
Arginine is known to improve lymphocyte-based immu-
nity (136). Arginine depletion due to upregulation of Arg1 
in myeloid-derived suppressor cells induces T-cell anergy, 
decreased proliferation of T cells, low expression of CD3 ζ‑chain 
T-cell receptor, and impairments of production of T cell cyto-
kines and of upregulation of cyclin d3 and cyclin-dependent 
kinase 4 (cdk4) (137). L‑arginine is essential for maturation 
of cd3+ and the proliferation of cd8+ T lymphocytes (138). 
Arginine is also critical for B-lymphocyte differentiation; in 
transgenic mice over‑expressing arginase in intestinal cells 
there was an impaired transition of pro- to pre-B cells in 
the bone marrow with marked decrease in B cell cellularity, 
serum IgM levels and number and size of Peyer's patches; this 
was reversed by arginine supplementation (139).
Noting the essential role of arginine for immunity, an 
arginine deficiency syndrome (ADS) was proposed, defined 
by pathological increase in arginase, decreased NO produc-
tion, decreased arginine availability, abnormal T cell function 
including loss of ζ-chain, and presence of one or more of: 
trauma, cancer, chronic infection, liver necrosis, pulmonary 
hypertension; treatment for AdS include L-arginine and the 
arginase inhibitors N‑hydroxy‑arginine (NOHA) and COX‑2 
inhibitors.
Ascorbate is also important for adaptive immune responses, 
starting with the observations that reducing environments 
make immune responses more efficient (140); it increases the 
levels of IFN produced by activated fibroblasts (141); improves 
neutrophil function by preserving/restoring function of their 
myeloperoxidase; is essential for lymphocyte development, 
stimulating the proliferation of NK cells (142); and has ample 
epigenetic effects through dioxygenases TET (ten‑eleven 
translocases) and Jumonji c (Jmjc)-domain-containing 
histone demethylases (131).
A comprehensive review of the actions of ascorbate 
including those on the immune system (131) concludes that 
enhancement of B- and T-cell differentiation and proliferation 
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  46:  489-508,  2020 501
is likely due to its effects on gene regulation; an epigenetic 
effect (dNA demethylation) of ascorbate on the cd8 receptor 
gene was also inferred in a series of lab experiments which 
concluded that ascorbate is necessary and sufficient for the 
CD8a gene transcriptional activation (140). A graphic repre-
sentation of these actions are given in Fig. 4.
Multiple authors noted that administration of ascorbate 
in chronic granulomatous disease led to consistent improve-
ments (143,144); more recent research showed that in 
human granulomas depletion of arginine by arginases from 
macrophages was associated with T-cell suppression without 
affecting their viability, via downregulation of T-cells recep-
tors (128).
Both arginine and ascorbate stimulate production of 
NO, which inhibits IDO (135), and its suppressive effects on 
lymphocyte proliferation; the simultaneous action of arginine 
(NO donor) and ascorbate (catalase inhibitor) is synergical 
for leukocytes function and especially apoptosis (134), yet 
another example of the arginine‑ascorbate antimicrobial 
synergy.
Synergistic action of arginine-ascorbate for inhibiting 
viral replication and achieving viral clearance is shown by 
the combined effect of IFN-α (induced by NO) and IFN-γ 
(induced by ascorbate) in inducing the antiviral response via 
ISGs, which is much enhanced when compared to either one 
alone (79,145). This was also seen with IFN‑β1 and IFN‑γ (146) 
in improved apoptosis, RNA degradation and inflammatory 
response; and also with TNF-α and IFN-β which together 
induced a novel synergistic antiviral state, highly distinct from 
that induced by either cytokine alone and involved >850 novel 
host cell genes (147); this was necessary and sufficient to 
completely block the replication and spread of myxoma virus 
in human fibroblasts and to block the spread of vaccinia virus 
and tanapox virus to neighboring cells.
Nitric oxide from arginine directly enhances the stimula-
tion of ascorbic acid on T cell proliferation, and this interaction 
is especially important in T cell recovery after stem cell 
transplantation (147), where generation and proliferation of 
T cells is greatly improved by ascorbate and blocking of NOS 
diminished this effect (142).
To simplify the arginine-ascorbate actions in the immune 
response by the way of dichotomy, arginine is an essential 
factor for the native immune response via NO production and 
activation of IFN-α/β (type I) while ascorbate is critical for 
the efficacy of the adaptive immunity via T cell proliferation 
and function via IFN-γ (type II); their synergy ensures both 
decreased viral replication and clearance.
c) Stimulation of tissue repair. It is known for decades that 
L‑arginine supplementation (3‑10 g/day) speeds wound 
healing and recovery after surgery (136); we also know that 
ascorbate is an essential cofactor for collagen synthesis, 
meaning that both arginine-ascorbate are required for tissue 
repair; additional molecules and pathways are involved in the 
immune response in viral infection and individual variability 
can also have an important role.
Figure 4. Antiviral actions of arginine and ascorbate.
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In a first step for tissue repair arginine is metabolized 
to ornithine by arginases (Arg1/2), resulting in both proline 
(collagen synthesis) and biologically active amines (putres-
ceine, spermidine, spermine) essential for cell repair and 
proliferation; the balance iNOS/Arg1 determines the pro‑ or 
anti-inflammatory environment and intra-cellular use of 
arginine. depending on this, macrophages are polarised in 
M1 (proinflamamtory, cytotoxic, NO) and M2 (anti‑inflam-
matory, proliferative, Arg1), and excessive activity of either 
can create pathologies; surprisingly the suppression of 
M2 activity in mice resulted in reduced lung fibrotic lesions 
in SARS-coV infection, suggesting the virus produces a shift 
to M2 activities, despite the high levels of inflammatory cyto-
kines (82,127,148).
Arginine corrects the pH and its increased extracel-
lular concentration helps cause a shift towards M2, and is 
the substrate for arginase, which is stimulated by uric acid. 
Arginases are activated by Mn2+ in a pH-dependent fashion, 
Arg1/2 have an alkaline optimum activity of 9.0‑9.5. NOHA, 
the arginase inhibitor, can also be oxidized to NO by many 
heme proteins, including hemoglobin, peroxidase, cyto-
chromes P-450, and catalase, which is inhibited by ascorbate, 
which is another mechanism by which ascorbate modulates 
redox and metabolic reactions and NO production (133).
While NO donors (SNAP, molsidomine) or iNOS gene 
transfer enhance wound collagen synthesis in a dose-dependent 
manner, high levels of NO strongly impair collagen synthesis 
probably due to inhibition of arginase.
Ascorbate helps reduce inflammation by limiting expres-
sion of pro-inflammatory cytokines, reducing cRP in 
individuals with CRP >1.0 mg/l (149); it scavenges ROS and 
reduces the oxidative stress on mitochondria (150), improves 
intracellular pH via decreasing lactate (151), decreases cell 
apoptosis and tissue necrosis also by inhibiting HIF‑1α (152), 
which is stimulated by IFN‑I (80); hypoxia by inhibiting argi-
nine intracellular synthesis is a deleterious factor for tissue 
regeneration.
To get a good perspective on the dose needed of argi-
nine‑ascorbate, we note that the daily plasma flux of arginine 
is about 22‑25 g with 5‑6 g from diet (153), the majority of 
arginine is synthesized in the liver and kidney (15‑20 g daily) 
from citrulline in the urea cycle, ~10% is used for creatine 
synthesis and 1% for NO generation (133). Pharmacological 
doses of up to 30 g/day for 2 weeks administered either 
intravenously or enteral in multiple clinical studies appear to 
be well tolerated by healthy individuals and cancer patients 
without major side effects; significant elevation in IGF1 was 
the only modified biomarker (153).
Ascorbate is sufficient in normal situations in doses 
of 50-250 mg daily for maintaining plasma levels 
>30 µg/ml, however, during stress and infections the need 
for ascorbate intake exceeds 1,000 mg/day and its intestinal 
absorbtion is optimal when administration is fractionated at 
~250‑350 mg per dose or in extended release forms (calcium 
ascorbate and slow‑release micronised preparations) (154).
In our experience (155) an effective antiviral regimen is the 
combination arginine+extended release vitamin C, in doses 
of 1,000 mg L‑arginine and 250‑500 mg calcium/sodium 
ascorbate (Ester‑C) or Cetebe (GSK) or other modified release 
vitamin c, at least 3 times a day each.
We have found this treatment effective in many types 
of viral infections, including common cold and flu (many 
of which are caused by coronaviruses), herpes labialis, 
zona zoster, and hepatitis c, including a chronic hepatitis c 
patient who had significant viral loads after 2 treatments with 
ribavirin+interferon, and undetectable at 5 years after intrave-
nous arginine-ascorbate.
Arginine‑ascorbate in severely ill patients. Metabolic acidosis 
is associated with hyper‑inflammation in ARDS patients, and 
administration of sodium bicarbonate for balancing pH can 
be limited by electrolyte imbalance and/or cardiovascular 
pathology. Arginine administration can improve pH via the 
buffering action of NH+ groups and additionally can provide 
an immunity boost to septic patients, however, the formation of 
NO (nitric oxide), which may induce relaxation of the vascular 
smooth muscle has raised concerns (156,157).
A very thorough review of arginine use in critical care 
has analyzed both the mechanistic concern of possible 
NO-induced vasodilatation, alongside other actions that argi-
nine has in the critically ill patient. This study has importantly 
discussed the multiple clinical trials and reports of arginine 
use in septic patients (158). During critical illness there is a 
severe arginine deficit following a 2/3 reduction in arginine 
synthesis and increased degradation due to a 4-fold increase of 
arginase activity, so that arginine becomes an essential need 
for supplementation (158). Decreased arginine is especially 
deleterious for the immune system, which produce excessive 
myeloid suppressor cells which induce a pro‑inflammatory 
state and suppress T lymphocytes, with reduced number of 
cd4+ cells which are also functionally deficient, as they lack 
the ζ-chain of its receptor.
clinical trials found that arginine shortened hospitaliza-
tions and decreased infections, and in severe sepsis (159) 
improved outcomes and decreased mortality; it also reversed 
septic shock without hemodynamic instability (160).
A better assessment of septic shock patients can be done 
by using the ratio of arginine and its metabolite asymmetric 
dimethyl arginine (AdMA), which can block NO produc-
tion and act as vasoconstrictor; a declining arginine/ADMA 
ratio was associated with increased mortality (161); while an 
increasing arginine/ADMA ratio in septic patients improved 
mortality (162,163). Also important is a report showing 
that intravenous administration in critically ill patients of 
supra-physiologic doses of arginine did not produce hemo-
dynamic instability (164); this may be due to a preferential 
uptake in septic patients of arginine by leukocytes compared 
to endothelial cells.
The review concludes that arginine is safe to administer 
and beneficial in critically ill patients, contributing to resolu-
tion of infection and improving morbidity and mortality (158).
Adding ascorbate makes administration of arginine even 
safer; in septic mice ascorbate administration prevented 
the impaired vasoconstriction and angiotensin actions and 
excessive vasodilation as much as the iNOS gene knockout, 
and greatly increased survival (165), seemingly by inhibiting 
excessive NO production.
An important fact is that ascorbate, which is known to be 
decreased in septic patients, is a cofactor required for adrenal 
synthesis of hormones and neurotransmitters including 
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cathecholamines (norepinephrine) and vasopressin (131), 
physiological vasopressors which otherwise need to be admin-
istered.
In septic patients ascorbate was shown to decrease 
mortality especially in the hyperinflammatory subphenotype 
characterized by high leukocyte count (>15,000/ml) and fever 
(>37.5˚C) (150). A meta‑analysis including 1,210 patients with 
sepsis showed that different daily doses of intravenous ascor-
bate were associated with different results, and only a dose 
between 3‑10 g/day resulted in decreased mortality, decreased 
need for vasopressor and mechanical ventilation, but not lower 
or higher doses (166).
In a prospective randomised placebo-controlled double 
blind trial ‑ CITRIS‑ALI ‑ ascorbate 50 mg/kg or placebo 
was given q 6 h intravenously for 96 h to 167 patients with 
sepsis and ARDS; no significant difference was seen at 96 h in 
organ dysfunction scores (SOFA), inflammation marker CRP 
or thrombomodulin (for vascular integrity) (167). However, 
patients treated with vitamin C had a significant benefit in 
28‑day mortality, transfer from ICU by hour 168, number of 
IcU-free days by day 28, and number of hospital-free days.
Hence in ascorbate deficiency, it is likely that when admin-
istered intravenously to hypotensive patients, ascorbate should 
be administered first, followed by a lower dose of arginine 
(ex 1500 mg ascorbate in 100‑200 ml normal saline followed 
by 1000 mg L‑arginine in 100 ml saline administered at 
1 ml/min).
Other medication should be added depending on the clinical 
and laboratory signs:  for the ‘ground glass’ image on imagis-
tics, which signals presence of intra-alveolar- and intravascular 
emboli, especially when d-dimer is elevated: administration 
of anticoagulant, heparin or fractionated heparin;  for signs 
of porphyria (spontaneous ecchymosis which do not change 
color) - chloroquine, amodiaquine, curcumin; for tachy-
cardic, tachyarrhythmic patients amiodarone 400 mg qd for 
a maximum 7 days;  for all patients and especially with high 
cholesterol, simvastatin for asthma patients, Montelukast 
and/or fexofenadine or other lipophilic antihistaminic and anti‑
inflammatory, preferably curcumin; for anti-inflammatory, 
analgesic actions - PPAR-α/γ agonists fenofibrate/pioglitasone 
or ABDH6 inhibitors KT185 and KT203 (which decrease 
macrophage activation and pain‑inflicting CCXl‑2 with allo-
dynia); rabeprazole for preventing gastritis and for possible 
antiviral effects; methylprednisolone was shown to be of 
benefit in COVID‑19 (4), and even with associated immune 
depression favoring viral replication, it can be considered for 
short-term in severely ill.
Practical measures ‑ prevention and early interventions. 
A majority of SARS-coV2 patients (85-90%) have mild to 
moderate forms of disease, however 10‑15% develop rapidly 
deteriorating forms with approximately half of those dying, 
and it is difficult to predict accurately the individual risk for 
developing severe disease besides advanced age and existing 
co-morbid conditions.
Unopposed or excessive viral replication is an important 
pathogenic mechanism through which the virus overwhelms 
the natural defenses of the body; besides a weakened immune 
response associated with chronic pathologies (cardiovascular, 
renal, hepatic, autoimmune and neoplasic), the virus has an 
advantage in tired or stressed individuals (with high cortisol and 
lactate/LDH levels) and by repeated exposure which increases 
the dose of the virus (doctors, nurses, medical personnel). 
Protective measures are very important for limiting exposure 
to the pathogen in vulnerable populations and also testing and 
treating early, as soon as possible after respiratory symptoms.
After infection and respiratory symptoms, prompt local 
treatment is very important: aerosol inhalation, nasal drops, 
throat sprays are very useful treatments. Water vapors hydrate 
the airway mucosa, increase the volume of ASL and help the 
natural clearance of the virus via mucus shedding. Adding to 
the inhaled vapors natural antimicrobials such as rosemary, 
basil, tea tree, mint, eucalyptus, thyme, onion, in fresh or dry 
form; throat or nasal sprays with propolis, argentum, basil, 
thyme, cumin will also help viral inactivation and decrease 
inflammation.
We propose arginine-ascorbate as the mainstay of anti-
viral treatment for SARS-coV2 and other coronaviruses, 
administered from the initial signs of infection until its 
resolution.
As much as NSAIds (non-steroidal antiinflammatory 
drugs) are not recommended (aspirin, ibuprofen, naproxene 
and indomethacin), possibly because of concomitant inhibition 
of PGd2, known to be elevated in elderly patients, and further 
elevated by SARS-coV infection and in more severe forms of 
COVID‑19 (73); however PGD2 has protective, anti‑inflamma-
tory actions, and blocking cyclooxygenase (COX) also inhibits 
PGd2, which further imbalances an already malfunctioning 
immune response.
Interestingly, NSAId-mediated curcumin (also a main 
protease inhibitor) is useful for alleviating inflammation and 
pain, and if rhinitis and conjunctive inflammation are present, 
an antihistaminic can be of help (fexofenadine also inhibits 
the main COVID‑19 protease). We have successfully used 
the curcumin/antihistaminic combination for pain of various 
types from sore throat to allodynia, in patients with allergies, 
increased PGd2, rheumatoid arthritis, and also for porphyria. 
Patients who cannot tolerate curcumin may use instead extracts 
of Boswellia serrata (400 mg tid) as anti‑inflammatory and 
analgesic; artemisinin can be a good substitute for chloroquine 
or amiodarone in patients with prolonged QT interval, cOPd 
or lung fibrosis.
Risk evaluation of CoV infected patients. Assessing the risk 
for progression to severe forms early on during coV infec-
tion is important for prompt individual treatment and medical 
resource management, and also to avoid imposing restriction 
on the whole population, knowing that 90% of infections are 
asymptomatic or can be treated outside hospital; this may 
allow shifting isolation measures from whole populations to 
truly at‑risk populations (168).
A two-pronged strategy of risk evaluation can be employed 
based on age and exposure risk: in younger individuals 
(≤55 years old) a specific panel for genetic risk factors which 
predispose to fatal CoV infections (rs78142040, rs9605146, 
rs3848719; NAMPT ‑ 1001G allele, POPDC3, PDE4B, 
ABCC1, TNFRS11 and DD genotype of ACE) may be more 
useful, especially in individuals with potential increased expo-
sure to the virus (eg., healthcare professionals). However, in 
patients most at-risk - elderly and with chronic co-morbidities, 
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evaluation with different testing panels can reasonably assess 
their risk for severe COVID19, starting with the evaluation 
of oxidative/peroxisomal status (catalase, malondialdehyde), 
inflammation - cRP, fibrinogen - and metabolism - bicar-
bonate, HgbA1c, lipid profile, and immune balance ‑ PGD2 and 
serum protein electrophoresis - for asymptomatic patients, and 
adding for symptomatic patients the cd3+, cd4+, cd8+ and 
NK counts (predictors of need for intensive care), LD1 isoen-
syme, which were good predictors for intensive care during 
the SARS epidemic (169); for hyper‑inflammatory status also 
useful are markers of neutrophil activation - MMP-9, LTB4, 
ferritin, CXCl‑2 (106).
Another approach to risk evaluation of severe cOV 
infection is measuring the high-sensitivity cardiac troponin 
(hs-cTnT), shown with data from the ARIc study to be a 
marker for end-organ damage in patients with chronic patholo-
gies (170); elevated troponin levels were also seen in some 
COVID‑19 patients (9).
Our efforts as front-line defenders against this invisible foe, 
SARS-coV, and possible others to come, are essential not only 
from a medical perspective but also towards fully regaining 
our individual and societal freedoms; through risk evaluation 
and prompt, effective treatments the burden of disease can be 
greatly diminished for both individuals and whole populations.
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